Filter Results

Clinical Studies

Open

  • Clonal Diversity of Freshly Taken ESD Specimens Rochester, Minn.

    Inclusion Criteria:

    • Patients with Barrett’s Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment.

    Exclusion Criteria: 

    • Patients without BE or EAC or that are not planned for ESD treatment.
  • Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma Mankato, Minn., Rochester, Minn., Jacksonville, Fla., La Crosse, Wis., Austin, Minn., Eau Claire, Wis., Scottsdale/Phoenix, Ariz. This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
  • Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE) (NO FEAR-BE) (NO FEAR-BE) Rochester, Minn.

    The purpose of this multicenter, prospective, single arm, non-randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or <50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.

Contact Us for the Latest Status

Closed for Enrollment

.